Celgene Co. (NASDAQ:CELG) saw a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 19,130,340 shares, a growth of 11.8% from the February 15th total of 17,114,939 shares. Based on an average daily trading volume, of 11,821,409 shares, the short-interest ratio is presently 1.6 days. Approximately 2.7% of the shares of the company are sold short.

In other Celgene news, Director James J. Loughlin sold 23,466 shares of the stock in a transaction dated Thursday, February 7th. The stock was sold at an average price of $87.29, for a total value of $2,048,347.14. Following the transaction, the director now owns 62,102 shares of the company’s stock, valued at $5,420,883.58. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director Ernest Mario bought 2,000 shares of the stock in a transaction on Tuesday, February 12th. The stock was purchased at an average cost of $89.99 per share, for a total transaction of $179,980.00. The disclosure for this purchase can be found here. Company insiders own 0.39% of the company’s stock.

A number of institutional investors and hedge funds have recently modified their holdings of CELG. Janney Capital Management LLC grew its holdings in Celgene by 2.9% during the 4th quarter. Janney Capital Management LLC now owns 4,219 shares of the biopharmaceutical company’s stock valued at $270,000 after buying an additional 120 shares in the last quarter. Pitcairn Co. grew its holdings in Celgene by 3.0% during the 4th quarter. Pitcairn Co. now owns 4,289 shares of the biopharmaceutical company’s stock valued at $275,000 after buying an additional 124 shares in the last quarter. Winthrop Advisory Group LLC grew its holdings in Celgene by 4.1% during the 4th quarter. Winthrop Advisory Group LLC now owns 3,171 shares of the biopharmaceutical company’s stock valued at $203,000 after buying an additional 125 shares in the last quarter. AE Wealth Management LLC grew its holdings in Celgene by 1.8% during the 4th quarter. AE Wealth Management LLC now owns 7,378 shares of the biopharmaceutical company’s stock valued at $473,000 after buying an additional 129 shares in the last quarter. Finally, Private Trust Co. NA grew its holdings in Celgene by 2.2% during the 4th quarter. Private Trust Co. NA now owns 6,245 shares of the biopharmaceutical company’s stock valued at $400,000 after buying an additional 132 shares in the last quarter. 74.19% of the stock is currently owned by institutional investors.

NASDAQ CELG opened at $88.29 on Friday. The company has a debt-to-equity ratio of 3.21, a quick ratio of 2.12 and a current ratio of 2.23. Celgene has a 52 week low of $58.59 and a 52 week high of $95.30. The stock has a market capitalization of $60.12 billion, a PE ratio of 11.60, a P/E/G ratio of 0.39 and a beta of 1.69.

Celgene (NASDAQ:CELG) last issued its earnings results on Thursday, January 31st. The biopharmaceutical company reported $2.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.32 by $0.07. The company had revenue of $4.04 billion for the quarter, compared to the consensus estimate of $3.98 billion. Celgene had a return on equity of 114.66% and a net margin of 26.48%. During the same quarter last year, the company earned $2.00 EPS. On average, equities analysts predict that Celgene will post 10.01 EPS for the current fiscal year.

A number of research analysts have weighed in on CELG shares. Morgan Stanley lowered their target price on Celgene from $93.00 to $88.00 and set an “equal weight” rating on the stock in a report on Wednesday, December 19th. Cowen started coverage on Celgene in a report on Tuesday, February 26th. They issued a “market perform” rating and a $102.00 target price on the stock. BidaskClub raised Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Zacks Investment Research raised Celgene from a “hold” rating to a “strong-buy” rating and set a $99.00 target price on the stock in a report on Wednesday, January 23rd. Finally, ValuEngine raised Celgene from a “strong sell” rating to a “sell” rating in a report on Friday, January 4th. Two research analysts have rated the stock with a sell rating, eleven have issued a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Hold” and a consensus target price of $100.94.

ILLEGAL ACTIVITY NOTICE: “Celgene Co. (CELG) Short Interest Up 11.8% in February” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2019/03/15/celgene-co-celg-short-interest-up-11-8-in-february.html.

About Celgene

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE to treat breast, non-small cell lung, pancreatic, and gastric cancers.

Recommended Story: How Buying a Call Option Works

Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.